US 2006/0142550 A1 · Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation

Abstract

Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-induced inflammation, such as artheriosclerosis and rheumatoid arthritis.

Claims1

Dependent claims

A monoclonal antibody produced by a hybridoma cell line having deposit number ______

Dependencies are inferred from the claim text.

Facts

Application

11/298,329Filed 2 Mar 2006

Priority

23 May 2003

Published

29 Jun 2006

Term ends

Not estimatedThe source records don’t support an estimate.

Classification3 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
C07K 2317/73
Characterized by effect upon binding to a cell or to an antigen: inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K
Peptides

Family

Application10/444,765Continuation in part · filed 23 May 2003

Application60/634,642Us provisional application · filed 9 Dec 2004

Application11/298,329Continuation in part · filed 2 Mar 2006

US 2004/0248097 A1Published application

US 7,435,800 B2Related patent

US 2006/0142550 A1This patent

From the US filing history. Foreign family members aren’t listed.

Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation

Life of this patent

Abstract

Claims1

Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation

Life of this patent

Abstract

Claims1